AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04293549 — intervention group
Intervention type: DRUG
Intervention: Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops
Description: rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment
Study NCT04574128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No retransfusion of cardiotomy blood
Description: No retransfusion of cardiotomy blood via heart- and lung mashine
Study NCT03329079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Technology Plus
Description: The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
Study NCT03329079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Technology
Description: The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
Study NCT00207948 — intervention group
Intervention type: DRUG
Intervention: Dose adjustment of Kaletra
Description: Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
Study NCT01923194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Purified Urofollitropin
Description: for Injection
Study NCT01923194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follitropin Alfa
Description: for Injection
Study NCT02632734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreBone Cone device
Description: coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
Study NCT02632734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreBone 500 device
Description: coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
Study NCT04013945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Superba Boost (Active)
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
Study NCT04013945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil (Placebo)
Description: To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
Study NCT05120102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: K2 diode laser of 980nm wavelength
Study NCT01385306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaCore System
Description: Non-invasive neurostimulation of the vagus nerve
Study NCT01846273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab
Study NCT01846273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab
Study NCT01846273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Description: Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Study NCT01846273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham PDT
Description: Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Study NCT00970008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks
Description: Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
Study NCT00970008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks
Description: Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
Study NCT00970008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 30 min sessions 1x/wk for 8 wks
Description: Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
Study NCT00970008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage 60 min session 1x/wk for 8 wks
Description: Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
Study NCT01569776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid formula
Description: Amino Acid baby formula
Study NCT01569776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Amino Acid Formula
Description: Hypoallergenic Baby formula
Study NCT00366041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermal substrate cellularised LG002 (10x10cm)
Description: application depending on burn injury surface
Study NCT00366041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal substrate uncellularised LG002 (10x10 cm)
Description: depending on burn injury surface
Study NCT05649735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn ovules
Description: LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.
Study NCT05649735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logusgyn Lavander
Description: LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13.
Study NCT05649735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution
Study NCT02249676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells
Study NCT02249676 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells
Study NCT03496857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
Study NCT03496857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bath Therapy
Description: The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
Study NCT02516410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661 plus ivacaftor combination
Study NCT02516410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02516410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-661 plus ivacaftor combination)
Study NCT02516410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ivacaftor)
Study NCT00996931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 2.5 mgs per day orally for 12 weeks
Study NCT04719234 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lung ultrasonography
Description: Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
Study NCT06098287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (Exhaust)
Description: Exhaust-only ventilation system
Study NCT06098287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (CFIS) and air filtration upgrades
Description: Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
Study NCT06098287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Residential mechanical ventilation system (ERV) and air filtration upgrades
Description: Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
Study NCT03440034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
Study NCT02406222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Chemotherapy
Study NCT02406222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Chemotherapy
Study NCT02406222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Chemotherapy
Study NCT02406222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Chemotherapy
Study NCT02406222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study NCT03622073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol treatment by Doctor
Description: Medical management of incomplete abortion
Study NCT02031302 — intervention group
Intervention type: DEVICE
Intervention: Lotus Valve System
Description: The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
Study NCT03085355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises and PNE
Description: Exercise for stretching and strength for neck muscles and pain neuroscience education
Study NCT01533077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg of BIA 9-1067 (single-dose)
Study NCT03085355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
Study NCT00258206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT03864068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03864068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: 1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
Study NCT02999009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trident II Tritanium Acetabular Shell
Description: A hemispherical acetabular shell indicated for cementless application.
Study NCT00956384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-stage dermal matrix/implant procedure
Description: One-stage breast reconstruction with dermal matrix and implant
Study NCT00956384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage tissue expander/implant procedure
Description: Two-stage breast reconstruction with tissue expander and implant
Study NCT00258206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT03882255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod dose range (2 - 20 mg)
Description: Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
Study NCT01574794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Description: The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
Study NCT00300326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer assist
Description: same implant using a computer-assisted surgical technique.
Study NCT02312713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based Exercise Training
Description: Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content.
Study NCT02312713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
Study NCT01574794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle stretching exercise
Description: The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
Study NCT03288753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Description: Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
Study NCT03288753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech intelligibility in quiet
Description: The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
Study NCT03288753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech intelligibility in noise
Description: The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
Study NCT03288753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRB (Vocale Rapide dans le Bruit)
Description: Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
Study NCT03775785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored enteral nutrition
Description: The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d.
Study NCT03873896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stimulated skin wrinkling test
Description: Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
Study NCT03873896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stimulated skin wrinkling test
Description: Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
Study NCT03873896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Nerve Block
Description: A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
Study NCT00761605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
Study NCT01404871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomipramine
Description: oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
Study NCT03206684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
Study NCT01404871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
Study NCT03206684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
Study NCT05142878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultracore Repose® mattress
Description: Residents will be placed on the Ultracore Repose® mattress during 14 days
Study NCT02779634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ubiquinol
Description: Ubiquinol three times daily
Study NCT02779634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill three times daily
Study NCT03882255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Propranolol
Description: Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
Study NCT03882255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Description: Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
Study NCT03041909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral drug
Study NCT00679068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
Study NCT02576873 — intervention group
Intervention type: OTHER
Intervention: Hemodiafiltration
Description: Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
Study NCT02470702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Study NCT02470702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)